Year-End Report

STANTON PARK GROUP for BARR LABORATORIES

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Consumer Issues/Safety/Products CSP

Generic Drug Settlements (S 316, HR 1902)

LobbyistCovered position, as disclosed
BRIAN CAVEY N/A
JAMES DERDERIAN N/A
ANDREW HALATAEI N/A
ERIN STRAWN N/A
ASHLIE VAN METER N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1902 (110th)

Pharmacy PHA

Generic Biologics (HR 1956, S 1695, HR 1038, S 623); FDA Reform (HR 2900, S 1082); Ofice of Generic Drugs funding in Agrigulture Appropriations (HR 3161, S 1859)

LobbyistCovered position, as disclosed
BRIAN CAVEY N/A
JAMES DERDERIAN N/A
ANDREW HALATAEI N/A
ERIN STRAWN N/A
ASHLIE VAN METER N/A

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3161 (110th), H.R. 1038 (110th), H.R. 1956 (110th), H.R. 2900 (110th)

Science/Technology SCI

Patent Reform (HR 1908, S 1145)

LobbyistCovered position, as disclosed
BRIAN CAVEY N/A
JAMES DERDERIAN N/A
ANDREW HALATAEI N/A
ERIN STRAWN N/A
ASHLIE VAN METER N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1908 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.